Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Section 6 of 6

References

277 sources

  1. AbbVie HUMIRA prescribing information (2025) (opens in a new tab)
  2. AbbVie SKYRIZI prescribing information (2026) (opens in a new tab)
  3. Abuabara et al. (2010) (opens in a new tab)
  4. Al Sawah et al. (2017) (opens in a new tab)
  5. Alinaghi et al. (2019) (opens in a new tab)
  6. Alumis and Kaken press release, collaboration and licensing agreement (2025) (opens in a new tab)
  7. Alumis corporate presentation, November 2026 (2026) (opens in a new tab)
  8. Alumis envudeucitinib for psoriasis page (opens in a new tab)
  9. Alumis expanded access policy page (opens in a new tab)
  10. Alumis Form 10-K (2026) (opens in a new tab)
  11. Alumis Form 10-Q, second quarter 2026 (2026) (opens in a new tab)
  12. Alumis Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
  13. Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026) (opens in a new tab)
  14. Alumis press release, AAD 2025 OLE data (2025) (opens in a new tab)
  15. Alumis press release, AAD 2026 ONWARD data (2026) (opens in a new tab)
  16. Alumis press release, Fall Clinical 2026 ONWARD data (2026) (opens in a new tab)
  17. Alumis press release, first quarter 2025 results (2025) (opens in a new tab)
  18. Alumis press release, first quarter 2026 results (2026) (opens in a new tab)
  19. Alumis press release, LUMUS topline results (2026) (opens in a new tab)
  20. Alumis press release, ONWARD1 and ONWARD2 topline results (2026) (opens in a new tab)
  21. Alumis press release, ONWARD3 topline results (2026) (opens in a new tab)
  22. Alumis press release, second quarter 2025 results (2025) (opens in a new tab)
  23. Alumis press release, second quarter 2026 results (2026) (opens in a new tab)
  24. Alumis press release, third quarter 2024 results (2024) (opens in a new tab)
  25. Alumis press release, third quarter 2025 results (2025) (opens in a new tab)
  26. Alumis press release, third quarter 2026 results (2026) (opens in a new tab)
  27. Alumis press release, year end 2024 results (2025) (opens in a new tab)
  28. Alumis press release, year end 2025 results (2026) (opens in a new tab)
  29. Alumis STRIDE protocol (2022) (opens in a new tab)
  30. Alumis STRIDE statistical analysis plan (2023) (opens in a new tab)
  31. Amgen ENBREL prescribing information (2026) (opens in a new tab)
  32. Amgen OTEZLA prescribing information (2025) (opens in a new tab)
  33. Andrzejczak et al. (2026) (opens in a new tab)
  34. ANZCTR ACTRN12621000011886 (opens in a new tab)
  35. Armstrong and Read (2020b) (opens in a new tab)
  36. Armstrong et al. (2012) (opens in a new tab)
  37. Armstrong et al. (2013a) (opens in a new tab)
  38. Armstrong et al. (2013b) (opens in a new tab)
  39. Armstrong et al. (2013c) (opens in a new tab)
  40. Armstrong et al. (2013d) (opens in a new tab)
  41. Armstrong et al. (2017a) (opens in a new tab)
  42. Armstrong et al. (2017b) (opens in a new tab)
  43. Armstrong et al. (2017c) (opens in a new tab)
  44. Armstrong et al. (2018) (opens in a new tab)
  45. Armstrong et al. (2019) (opens in a new tab)
  46. Armstrong et al. (2020a) (opens in a new tab)
  47. Armstrong et al. (2021) (opens in a new tab)
  48. Armstrong et al. (2023a) (opens in a new tab)
  49. Armstrong et al. (2023b) (opens in a new tab)
  50. Armstrong et al. (2023c) (opens in a new tab)
  51. Armstrong et al. (2024) (opens in a new tab)
  52. Armstrong et al. (2025a) (opens in a new tab)
  53. Armstrong et al. (2025b) (opens in a new tab)
  54. Armstrong et al. (2025c) (opens in a new tab)
  55. Armstrong et al. (2026a) (opens in a new tab)
  56. Armstrong et al. (2026b) (opens in a new tab)
  57. Armstrong et al. (2026c) (opens in a new tab)
  58. Augustin et al. (2010) (opens in a new tab)
  59. Augustin et al. (2024) (opens in a new tab)
  60. Basra et al. (2007) (opens in a new tab)
  61. Bausch Health SILIQ prescribing information (2026) (opens in a new tab)
  62. Bellinato et al. (2022) (opens in a new tab)
  63. Bissonnette et al. (2018) (opens in a new tab)
  64. Bissonnette et al. (2025) (opens in a new tab)
  65. Blauvelt et al. (2021) (opens in a new tab)
  66. Blauvelt et al. (2024a) (opens in a new tab)
  67. Blauvelt et al. (2024b) (opens in a new tab)
  68. Blauvelt et al. (2025a) (opens in a new tab)
  69. Blauvelt et al. (2025b) (opens in a new tab)
  70. Blauvelt et al. (2026a) (opens in a new tab)
  71. Blauvelt et al. (2026b) (opens in a new tab)
  72. Blauvelt et al. (2026c) (opens in a new tab)
  73. Blauvelt et al. (2026d) (opens in a new tab)
  74. Bowles et al. (2025) (opens in a new tab)
  75. Bożek and Reich (2017) (opens in a new tab)
  76. Brezinski et al. (2015) (opens in a new tab)
  77. Bristol Myers Squibb press release, BMS Patient Connect platform (2025) (opens in a new tab)
  78. Bristol Myers Squibb SOTYKTU prescribing information (2026) (opens in a new tab)
  79. Budu-Aggrey et al. (2019) (opens in a new tab)
  80. Burshtein and Schlesinger (2026) (opens in a new tab)
  81. Burshtein et al. (2021) (opens in a new tab)
  82. California HCAI new prescription drugs introduced to market, January to October 2026 (2026) (opens in a new tab)
  83. California HCAI prescription drug WAC increases, January to October 2026 (2026) (opens in a new tab)
  84. Carlisle et al. (2020) (opens in a new tab)
  85. Carrico et al. (2020) (opens in a new tab)
  86. Chat et al. (2024) (opens in a new tab)
  87. Chen et al. (2025) (opens in a new tab)
  88. ClinicalTrials.gov NCT05330858 (opens in a new tab)
  89. ClinicalTrials.gov NCT05330858 version 1 (opens in a new tab)
  90. ClinicalTrials.gov NCT05431634 (opens in a new tab)
  91. ClinicalTrials.gov NCT05431634 version 1 (opens in a new tab)
  92. ClinicalTrials.gov NCT05600036 (opens in a new tab)
  93. ClinicalTrials.gov NCT05600036 results (opens in a new tab)
  94. ClinicalTrials.gov NCT05600036 version 1 (opens in a new tab)
  95. ClinicalTrials.gov NCT05739435 (opens in a new tab)
  96. ClinicalTrials.gov NCT05739435 version 1 (opens in a new tab)
  97. ClinicalTrials.gov NCT06586112 (opens in a new tab)
  98. ClinicalTrials.gov NCT06586112 API record (opens in a new tab)
  99. ClinicalTrials.gov NCT06586112 version 1 (opens in a new tab)
  100. ClinicalTrials.gov NCT06588738 (opens in a new tab)
  101. ClinicalTrials.gov NCT06588738 version 1 (opens in a new tab)
  102. ClinicalTrials.gov NCT06846541 (opens in a new tab)
  103. ClinicalTrials.gov NCT06952634 (opens in a new tab)
  104. ClinicalTrials.gov NCT06952634 version 1 (opens in a new tab)
  105. ClinicalTrials.gov NCT06962774 (opens in a new tab)
  106. ClinicalTrials.gov NCT06962774 version 1 (opens in a new tab)
  107. ClinicalTrials.gov NCT07378579 (opens in a new tab)
  108. CMS 2026 QCDR measure specifications (2026) (opens in a new tab)
  109. CMS fact sheet, third cycle of negotiation (2026) (opens in a new tab)
  110. CMS Medicare Part B payment limit file (2026) (opens in a new tab)
  111. CMS MIPS Quality ID 410 specification (2026) (opens in a new tab)
  112. CMS MIPS Quality ID 485 specification (2026) (opens in a new tab)
  113. CMS negotiated prices fact sheet (2025) (opens in a new tab)
  114. De Luca et al. (2026) (opens in a new tab)
  115. Dendrou et al. (2016) (opens in a new tab)
  116. Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026) (opens in a new tab)
  117. Dhana et al. (2019) (opens in a new tab)
  118. Dowlatshahi et al. (2014) (opens in a new tab)
  119. Eder et al. (2016) (opens in a new tab)
  120. Eghlileb et al. (2007) (opens in a new tab)
  121. Egilman et al. (2024) (opens in a new tab)
  122. Ehst et al. (2026) (opens in a new tab)
  123. Eli Lilly TALTZ prescribing information (2024) (opens in a new tab)
  124. Elmets et al. (2019a) (opens in a new tab)
  125. Elmets et al. (2019b) (opens in a new tab)
  126. Elmets et al. (2021) (opens in a new tab)
  127. EMA psoriasis clinical investigation guideline (2004) (opens in a new tab)
  128. EU Clinical Trials Register 2022-002633-34 (opens in a new tab)
  129. FDA UNII record for envudeucitinib (opens in a new tab)
  130. Feldman et al. (2015) (opens in a new tab)
  131. Feldman et al. (2016) (opens in a new tab)
  132. Feldman et al. (2018a) (opens in a new tab)
  133. Feldman et al. (2018b) (opens in a new tab)
  134. Feldman et al. (2019) (opens in a new tab)
  135. Fredriksson and Pettersson (1978) (opens in a new tab)
  136. Fu et al. (2018) (opens in a new tab)
  137. GBD 2019 IMID Collaborators (2023) (opens in a new tab)
  138. Gelfand et al. (2006) (opens in a new tab)
  139. Gelfand et al. (2007) (opens in a new tab)
  140. Gooderham et al. (2025) (opens in a new tab)
  141. Griffiths et al. (2021) (opens in a new tab)
  142. Grossschaedl et al. (2024) (opens in a new tab)
  143. Gu et al. (2025) (opens in a new tab)
  144. Guo et al. (2024) (opens in a new tab)
  145. Hagino et al. (2025) (opens in a new tab)
  146. Hawkes et al. (2017) (opens in a new tab)
  147. Hawkes et al. (2019) (opens in a new tab)
  148. Hawkes et al. (2026) (opens in a new tab)
  149. Hawro et al. (2015) (opens in a new tab)
  150. Health Research Authority research summary, ESK-001 metformin and paroxetine study (2025) (opens in a new tab)
  151. Helmick et al. (2014) (opens in a new tab)
  152. Hendrix et al. (2018) (opens in a new tab)
  153. Hongbo et al. (2005) (opens in a new tab)
  154. Icen et al. (2009) (opens in a new tab)
  155. ICER targeted immunomodulators for plaque psoriasis final evidence report (2016) (opens in a new tab)
  156. ICER targeted immunomodulators for plaque psoriasis final evidence report (2018) (opens in a new tab)
  157. ICH E1 population exposure guideline (1995) (opens in a new tab)
  158. Imafuku et al. (2023) (opens in a new tab)
  159. Ishihara et al. (2026) (opens in a new tab)
  160. Jalenques et al. (2022) (opens in a new tab)
  161. Janssen ICOTYDE prescribing information (2026) (opens in a new tab)
  162. Janssen REMICADE prescribing information (2025) (opens in a new tab)
  163. Janssen STELARA prescribing information (2026) (opens in a new tab)
  164. Janssen TREMFYA prescribing information (2026) (opens in a new tab)
  165. Jaworecka et al. (2021) (opens in a new tab)
  166. Jensen et al. (2023) (opens in a new tab)
  167. Jia et al. (2022) (opens in a new tab)
  168. Karpoff et al. (2026) (opens in a new tab)
  169. Kim et al. (2025) (opens in a new tab)
  170. Kong and Buzney (2026) (opens in a new tab)
  171. Korman et al. (2016) (opens in a new tab)
  172. Krueger et al. (2022) (opens in a new tab)
  173. Kumar et al. (2026) (opens in a new tab)
  174. Kurd and Gelfand (2009) (opens in a new tab)
  175. Kurd et al. (2010) (opens in a new tab)
  176. Langley et al. (2015) (opens in a new tab)
  177. Lebwohl et al. (2014) (opens in a new tab)
  178. Lebwohl et al. (2022) (opens in a new tab)
  179. Lebwohl et al. (2026a) (opens in a new tab)
  180. Lebwohl et al. (2026b) (opens in a new tab)
  181. Lønnberg et al. (2013) (opens in a new tab)
  182. Lovell et al. (2025) (opens in a new tab)
  183. Magnolo et al. (2026) (opens in a new tab)
  184. Marquez-Grap et al. (2025) (opens in a new tab)
  185. Martínez-García et al. (2014) (opens in a new tab)
  186. McCoy et al. (2023) (opens in a new tab)
  187. Mehrotra et al. (2026) (opens in a new tab)
  188. Mehta et al. (2010) (opens in a new tab)
  189. Menter et al. (2019) (opens in a new tab)
  190. Menter et al. (2020) (opens in a new tab)
  191. Merola et al. (2021) (opens in a new tab)
  192. Motedayen Aval et al. (2025) (opens in a new tab)
  193. Mrowietz et al. (2025) (opens in a new tab)
  194. Murage et al. (2018) (opens in a new tab)
  195. Narayan et al. (2025) (opens in a new tab)
  196. Narayan et al. (2026a) (opens in a new tab)
  197. Narayan et al. (2026b) (opens in a new tab)
  198. Nast et al. (2026a) (opens in a new tab)
  199. Nast et al. (2026b) (opens in a new tab)
  200. National Psoriasis Foundation position statement on psoriasis severity (2025) (opens in a new tab)
  201. National Psoriasis Foundation, FDA drops TB testing for Skyrizi (2026) (opens in a new tab)
  202. National Psoriasis Foundation, TB testing for new oral treatment (2026) (opens in a new tab)
  203. Noh et al. (2025) (opens in a new tab)
  204. Noot et al. (2026) (opens in a new tab)
  205. Novartis COSENTYX prescribing information (2026) (opens in a new tab)
  206. Novartis NEORAL prescribing information (2023) (opens in a new tab)
  207. Papp et al. (2015) (opens in a new tab)
  208. Papp et al. (2021) (opens in a new tab)
  209. Papp et al. (2024) (opens in a new tab)
  210. Papp et al. (2025a) (opens in a new tab)
  211. Papp et al. (2025b) (opens in a new tab)
  212. Papp et al. (2025c) (opens in a new tab)
  213. Papp et al. (2026) (opens in a new tab)
  214. Parisi et al. (2020) (opens in a new tab)
  215. Park et al. (2024) (opens in a new tab)
  216. Pasumarthi et al. (2026) (opens in a new tab)
  217. Patel et al. (2026) (opens in a new tab)
  218. Paul et al. (2015) (opens in a new tab)
  219. Pelet Del Toro et al. (2023) (opens in a new tab)
  220. Perlmutter et al. (2026) (opens in a new tab)
  221. Pilon et al. (2019) (opens in a new tab)
  222. Piragine et al. (2022) (opens in a new tab)
  223. Popatia et al. (2019) (opens in a new tab)
  224. Raharja et al. (2021) (opens in a new tab)
  225. Reich et al. (2021) (opens in a new tab)
  226. Rome et al. (2025) (opens in a new tab)
  227. Ryan et al. (2015) (opens in a new tab)
  228. Sbidian et al. (2025) (opens in a new tab)
  229. Schaefer et al. (2015) (opens in a new tab)
  230. Schneiderman and Derrick (2026) (opens in a new tab)
  231. Semenov et al. (2021) (opens in a new tab)
  232. Shah et al. (2024) (opens in a new tab)
  233. Shorla Oncology JYLAMVO prescribing information (2026) (opens in a new tab)
  234. Smith et al. (2024a) (opens in a new tab)
  235. Smith et al. (2024b) (opens in a new tab)
  236. Smith et al. (2025) (opens in a new tab)
  237. Snyder et al. (2023) (opens in a new tab)
  238. Spuls et al. (2010) (opens in a new tab)
  239. Stein Gold et al. (2025) (opens in a new tab)
  240. Stein Gold et al. (2026a) (opens in a new tab)
  241. Stein Gold et al. (2026b) (opens in a new tab)
  242. Stiefel SORIATANE prescribing information (2023) (opens in a new tab)
  243. Strober et al. (2019) (opens in a new tab)
  244. Strober et al. (2020) (opens in a new tab)
  245. Strober et al. (2023) (opens in a new tab)
  246. Strober et al. (2025) (opens in a new tab)
  247. Stuart et al. (2022) (opens in a new tab)
  248. Sun Pharma ILUMYA prescribing information (2026) (opens in a new tab)
  249. Takeda press release, LATITUDE Atlas results (2026) (opens in a new tab)
  250. Takeda press release, zasocitinib NDA acceptance (2026) (opens in a new tab)
  251. Takeda press release, zasocitinib skin clearance across body sites (2026) (opens in a new tab)
  252. Takeshita et al. (2015) (opens in a new tab)
  253. Teeple and Fitzgerald (2022) (opens in a new tab)
  254. Teeple and Muser (2019) (opens in a new tab)
  255. Texas DSHS 2026 annual WAC report (2026) (opens in a new tab)
  256. Tilley et al. (2024) (opens in a new tab)
  257. Tilley et al. (2026) (opens in a new tab)
  258. Tsai et al. (2024) (opens in a new tab)
  259. UCB BIMZELX prescribing information (2024) (opens in a new tab)
  260. UCB CIMZIA prescribing information (2025) (opens in a new tab)
  261. Ucpinar et al. (2024a) (opens in a new tab)
  262. Ucpinar et al. (2024b) (opens in a new tab)
  263. Ucpinar et al. (2024c) (opens in a new tab)
  264. Vanderpuye-Orgle et al. (2015) (opens in a new tab)
  265. Vazquez et al. (2023) (opens in a new tab)
  266. Villacorta et al. (2020) (opens in a new tab)
  267. Wan et al. (2020) (opens in a new tab)
  268. World Health Organization INN stem book (2024) (opens in a new tab)
  269. World Health Organization proposed INN list 130 (2023) (opens in a new tab)
  270. Wu et al. (2018) (opens in a new tab)
  271. Wu et al. (2021) (opens in a new tab)
  272. Wu et al. (2023) (opens in a new tab)
  273. Xu et al. (2023) (opens in a new tab)
  274. Yang et al. (2022) (opens in a new tab)
  275. Zhao et al. (2019) (opens in a new tab)
  276. Zheng et al. (2024) (opens in a new tab)
  277. Zhou et al. (2025) (opens in a new tab)